Akèy › Kansè Poumon ki pa ti selil › Kalifòni › Mountain View
Etid klinik pou Kansè Poumon ki pa ti selil nan Mountain View, CA
21 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote Mountain View (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Ap rekriteFaz 1/2
- Stanford Cancer Institute (Melanoma/NSCLC), Stanford · 5 mi lwen
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Ap rekriteFaz 3
- Palo Alto Medical Foundation-Camino Division, Mountain View
- Palo Alto Medical Foundation Health Care, Palo Alto · 5 mi lwen
- Stanford Cancer Institute Palo Alto, Palo Alto · 5 mi lwen
Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC
Ap rekriteFaz 3
- Stanford University, Stanford · 5 mi lwen
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Ap rekriteFaz 2
- Stanford Cancer Institute, Stanford · 5 mi lwen
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Ap rekriteEtid obsèvasyon
- Stanford University, Palo Alto · 5 mi lwen
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
Ap rekriteFaz 2
- Stanford Cancer Institute, Stanford · 5 mi lwen
- Stanford Hospital and Clinics, Stanford · 5 mi lwen
- Stanford Hospital Investigational Drug Services, Stanford · 5 mi lwen
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Stanford Cancer Center, Palo Alto · 5 mi lwen
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Ap rekriteFaz 1/2
- Stanford Cancer Institute, Stanford · 5 mi lwen
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
Ap rekriteFaz 1/2
- Stanford University Medical Center - Neurology, Stanford · 5 mi lwen
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Palo Alto Medical Foundation Research Center, Palo Alto · 5 mi lwen
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 1/2
- Stanford Cancer Institute, Stanford · 5 mi lwen
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Ap rekriteFaz 1/2
- Stanford University Medical Center, Stanford · 5 mi lwen
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Ap rekriteFaz 1
- Stanford University Medical Center, Palo Alto · 5 mi lwen
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Ap rekriteFaz 1
- Stanford University, Palo Alto · 5 mi lwen
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Ap rekriteFaz 1/2
- Stanford University - Stanford Cancer Institute, Stanford · 5 mi lwen
A Study of LY4175408 in Participants With Advanced Cancer
Ap rekriteFaz 1
- Stanford Medicine Cancer Center, Stanford · 5 mi lwen
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Ap rekriteFaz 1/2
- Stanford University, Stanford · 5 mi lwen
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Ap rekriteFaz 1/2
- Stanford Women's Cancer Center, Palo Alto · 5 mi lwen
Engagement of Veterans With Lung Cancer
Ap rekrite
- Veterans Affairs Palo Alto Health Care System (VAPAHCS), Palo Alto · 5 mi lwen
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Stanford · 5 mi lwen
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Ap rekriteFaz 1
- Stanford University, Stanford · 5 mi lwen
Etid Kansè Poumon ki pa ti selil nan lòt vil
- Houston, TX145 etid
- New York City, NY121 etid
- Arlington, VA104 etid
- Nashville, TN97 etid
- Boston, MA90 etid
- Los Angeles, CA87 etid
- St. Louis, MO73 etid
- Chicago, IL61 etid
- Baltimore, MD60 etid
- San Antonio, TX59 etid
- Columbus, OH57 etid
- Washington, DC55 etid
Lòt etid nan Mountain View
- Kansè (tout kalite)40 etid
- Kansè nan tete26 etid
- Kansè Metastatik25 etid
- Leksemi mieloïd egi19 etid
- Kansè ovè19 etid
- Twoub Spektòm Otis17 etid
- Kansè poumon17 etid
- Kansè pwostat15 etid
- Ensifizyans kadyak15 etid
- Otis13 etid
- Leksemi limfoblastik egi13 etid
- Kansè kolorektal13 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.